原发性肝癌患者介入治疗前后血清GPC3水平检测的临床价值

Clinical significance of glypican-3 serum levels in patients with hepatocellar carcinoma of interventional therapy

目的:了解原发性肝癌(hepatocellar carcinoma,HCC)介入治疗前后GPC3的浓度变化和临床价值。方法:采用ELISA法检测HCC、肝硬化、正常人血清GPC3浓度。结果:51例HCC患者、16例肝硬化患者、正常人组血清GPC3浓度分别为(3939.72±2801.92)、(619.08±542.80)和(534.24±500.20)pg/mL,前者与后二者比较差异有统计学意义(P<0.05),但其表达与血清甲胎蛋白(alpha-fetoprotein,AFP)无显著相关性;32例HCC患者介入治疗后高转移复发倾向组血清GPC3浓度为(4418.00±3941.96)pg/mL,低转移复发倾向组血清GPC3浓度为(534.44±910.56)pg/mL,二者比较差异有统计学意义(P<0.05);缓解组、稳定组、恶化组血清GPC3浓度分别为(571.64±288.72)、(2521.76±2340.76)、(4812.84±1858.64)pg/mL,3组两两比较差异均有统计学意义(P<0.05)。结论:GPC3在HCC患者血清中的检出率高,特异性强,其表达与AFP无相关性,联合应用AFP及GPC3可提高诊断的灵敏度。GPC3与肿瘤复发转移、治疗效果有关。

Objective： To study the clinical significance of serum glypican-3 in patients with hepatocellar carcinoma who underwent interventional therapy. Methods： Serum levis of glypican-3 were detected with ELISA in patients with hepatocellar carcinoma,cirrhosis and normal people. Re. suits： Serum levels of glypican-3 in patients with hepatocellar carcinoma （52 cases）were significantly higher than those with cirrhosis （16 cases） or healthy group（30 cases） （P〈0.05）. But with the serum AFP there was no significant correlation, GPC3 in higher group to matastasis and recurrence were significantly higher than the lower one （P〈0.05）. There was a significant difference of GPC3 between mitigation group, stabie group and deterioration group（P〈0;05）.Conclusion： GPC3 in patients with hepatocarcinoma is high,and doesn＇t have in patients with hepatocarcinoma is high ,and correlation with AFP Joint Detecti6n G PC3 and AFP may improve the diagnOstiC sensitivity.GPC3 may be associated with the tumor recurrence ,metastasis and treament.